Dynamic QT/RR relationship of cardiac conduction in premature infants treated with low-dose doxapram hydrochloride

Masafumi Miyata, Tadayoshi Hata, Noriko Kato, Masatomo Takeuchi, Hiroko Mizutani, Masamichi Kubota, Toshio Yamazaki

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Doxapram hydrochloride, a respiratory stimulant, has several undesirable side effects during high-dose administration, including second-degree atrioventricular (AV) block and QT prolongation. In Japan, this drug is contraindicated for newborn infants. Recent studies, however, have demonstrated the efficacy and safety of doxapram therapy for apnea of prematurity (AOP) using lower doses than those previously tested. As a result, approximately 60% of Japanese neonatologists continue to use this drug. This study used surface ECG recordings to assess the cardiac safety of low-dose doxapram hydrochloride (0.2 mg/kg/h) in fifteen premature very-low-birth-weight infants with idiopathic AOP. Cardiac intervals and number of apnea episodes were compared before and after drug administration. Low-dose doxapram hydrochloride resulted in approximately 90% reduction in the frequency of apnea without side effects. None of the infants developed QT or PR prolongation, arrhythmia, or other conduction disorders. In addition, there was no change in the slope of QT/RR before versus after administration of doxapram hydrochloride. We conclude that low-dose administration of doxapram hydrochloride did not have any undesirable effects on myocardial depolarization and repolarization.

Original languageEnglish
Pages (from-to)330-333
Number of pages4
JournalJournal of Perinatal Medicine
Volume35
Issue number4
DOIs
Publication statusPublished - 01-08-2007

Fingerprint

Doxapram
Premature Infants
Apnea
Respiratory System Agents
Pharmaceutical Preparations
Safety
Very Low Birth Weight Infant
Atrioventricular Block
Cardiac Arrhythmias
Japan
Electrocardiography
Newborn Infant

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynaecology

Cite this

Miyata, Masafumi ; Hata, Tadayoshi ; Kato, Noriko ; Takeuchi, Masatomo ; Mizutani, Hiroko ; Kubota, Masamichi ; Yamazaki, Toshio. / Dynamic QT/RR relationship of cardiac conduction in premature infants treated with low-dose doxapram hydrochloride. In: Journal of Perinatal Medicine. 2007 ; Vol. 35, No. 4. pp. 330-333.
@article{62d21a75852647f696b7e3faf6f196c6,
title = "Dynamic QT/RR relationship of cardiac conduction in premature infants treated with low-dose doxapram hydrochloride",
abstract = "Doxapram hydrochloride, a respiratory stimulant, has several undesirable side effects during high-dose administration, including second-degree atrioventricular (AV) block and QT prolongation. In Japan, this drug is contraindicated for newborn infants. Recent studies, however, have demonstrated the efficacy and safety of doxapram therapy for apnea of prematurity (AOP) using lower doses than those previously tested. As a result, approximately 60{\%} of Japanese neonatologists continue to use this drug. This study used surface ECG recordings to assess the cardiac safety of low-dose doxapram hydrochloride (0.2 mg/kg/h) in fifteen premature very-low-birth-weight infants with idiopathic AOP. Cardiac intervals and number of apnea episodes were compared before and after drug administration. Low-dose doxapram hydrochloride resulted in approximately 90{\%} reduction in the frequency of apnea without side effects. None of the infants developed QT or PR prolongation, arrhythmia, or other conduction disorders. In addition, there was no change in the slope of QT/RR before versus after administration of doxapram hydrochloride. We conclude that low-dose administration of doxapram hydrochloride did not have any undesirable effects on myocardial depolarization and repolarization.",
author = "Masafumi Miyata and Tadayoshi Hata and Noriko Kato and Masatomo Takeuchi and Hiroko Mizutani and Masamichi Kubota and Toshio Yamazaki",
year = "2007",
month = "8",
day = "1",
doi = "10.1515/JPM.2007.068",
language = "English",
volume = "35",
pages = "330--333",
journal = "Journal of Perinatal Medicine",
issn = "0300-5577",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "4",

}

Dynamic QT/RR relationship of cardiac conduction in premature infants treated with low-dose doxapram hydrochloride. / Miyata, Masafumi; Hata, Tadayoshi; Kato, Noriko; Takeuchi, Masatomo; Mizutani, Hiroko; Kubota, Masamichi; Yamazaki, Toshio.

In: Journal of Perinatal Medicine, Vol. 35, No. 4, 01.08.2007, p. 330-333.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dynamic QT/RR relationship of cardiac conduction in premature infants treated with low-dose doxapram hydrochloride

AU - Miyata, Masafumi

AU - Hata, Tadayoshi

AU - Kato, Noriko

AU - Takeuchi, Masatomo

AU - Mizutani, Hiroko

AU - Kubota, Masamichi

AU - Yamazaki, Toshio

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Doxapram hydrochloride, a respiratory stimulant, has several undesirable side effects during high-dose administration, including second-degree atrioventricular (AV) block and QT prolongation. In Japan, this drug is contraindicated for newborn infants. Recent studies, however, have demonstrated the efficacy and safety of doxapram therapy for apnea of prematurity (AOP) using lower doses than those previously tested. As a result, approximately 60% of Japanese neonatologists continue to use this drug. This study used surface ECG recordings to assess the cardiac safety of low-dose doxapram hydrochloride (0.2 mg/kg/h) in fifteen premature very-low-birth-weight infants with idiopathic AOP. Cardiac intervals and number of apnea episodes were compared before and after drug administration. Low-dose doxapram hydrochloride resulted in approximately 90% reduction in the frequency of apnea without side effects. None of the infants developed QT or PR prolongation, arrhythmia, or other conduction disorders. In addition, there was no change in the slope of QT/RR before versus after administration of doxapram hydrochloride. We conclude that low-dose administration of doxapram hydrochloride did not have any undesirable effects on myocardial depolarization and repolarization.

AB - Doxapram hydrochloride, a respiratory stimulant, has several undesirable side effects during high-dose administration, including second-degree atrioventricular (AV) block and QT prolongation. In Japan, this drug is contraindicated for newborn infants. Recent studies, however, have demonstrated the efficacy and safety of doxapram therapy for apnea of prematurity (AOP) using lower doses than those previously tested. As a result, approximately 60% of Japanese neonatologists continue to use this drug. This study used surface ECG recordings to assess the cardiac safety of low-dose doxapram hydrochloride (0.2 mg/kg/h) in fifteen premature very-low-birth-weight infants with idiopathic AOP. Cardiac intervals and number of apnea episodes were compared before and after drug administration. Low-dose doxapram hydrochloride resulted in approximately 90% reduction in the frequency of apnea without side effects. None of the infants developed QT or PR prolongation, arrhythmia, or other conduction disorders. In addition, there was no change in the slope of QT/RR before versus after administration of doxapram hydrochloride. We conclude that low-dose administration of doxapram hydrochloride did not have any undesirable effects on myocardial depolarization and repolarization.

UR - http://www.scopus.com/inward/record.url?scp=34447120822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447120822&partnerID=8YFLogxK

U2 - 10.1515/JPM.2007.068

DO - 10.1515/JPM.2007.068

M3 - Article

C2 - 17614751

AN - SCOPUS:34447120822

VL - 35

SP - 330

EP - 333

JO - Journal of Perinatal Medicine

JF - Journal of Perinatal Medicine

SN - 0300-5577

IS - 4

ER -